Heplatinum Pharmaceuticals is committed to promoting global antibody drug innovation and development
Platinum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative drugs. The company has a first-class management team and an excellent talent team. Since its establishment, the company has established an antibody drug discovery platform centered on the Harbour Mice and HBICE platforms, and has established a rich product pipeline with excellent R&D capabilities, covering the two major fields of oncology and autoimmune diseases. Of these, 2 assets have entered critical clinical phase III near commercialization, and 10 clinical trials are progressing rapidly. The company's unique market positioning enabled it to rapidly lead innovative antibody therapies in the field of oncology and immunity.
Three core technology platforms help differentiated pipeline development
The company built a scarce leading core technology platform with Harbour MICE and HBice platforms as the core R&D engine for the company's differentiated pipelines. The development of the three major platforms is difficult, the technical barriers are high, and the platforms are highly scarce. There have been many major international transactions involving similar platforms, and there is great commercial potential. At the same time, the company has now continued to promote joint development strategies with more than 50 advanced partners around the world to maximize the value of the platform.
Bartolizumab and tenacip are potentially the best in their class. Commercialization of bartolizumab is a breakthrough treatment for autoimmune diseases, showing good therapeutic potential in indications such as myasthenia gravis, neuromyelitis spectrum diseases, immune thrombocytopenia, and thyroid-related eye diseases. Currently, clinical progress of bartolizumab is progressing rapidly, and it is expected that it will be approved for marketing in 2023. Meanwhile, tenacept is expected to become the first globally innovative biopharmaceutical in the field of dry eye disease in China. Its clinical progress is smooth, and it is expected to be approved for marketing in 2023.
The company's multiple potential pipeline projects are advancing at an accelerated pace. To meet the different needs of patients around the world, the company has established diversified and differentiated pipelines covering tumors and autoimmune diseases. A number of potential pipeline projects targeting different indications such as solid tumors, hematoma, and severe asthma are advancing at an accelerated pace. HBM4003 and HBM9022 are currently in clinical phase I. The research and development of HBM1022, HBM7008, HBM1020, HBM1007, and is progressing smoothly. It is expected that IND applications will be submitted around 2022. HBM7020
Profit Forecasts and Ratings:
The net profit attributable to the company in 2022-2024 is estimated to be -884 million yuan, -944 million yuan, and -858 million yuan respectively. DCF estimates that the company's internal (reasonable) value should be HK$780, covering the “buy” rating for the first time.
Risk warning:
Risk of failure in new drug development; risk of review progress falling short of expectations; patent risk; risk of increased industry competition; risk of medical insurance fee control